Clinical Trial

Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-arm, open-label study designed to evaluate the safety, tolerability and cellular pharmacokinetic profiles of UTAA07 Injection. It also aims to preliminarily assess the efficacy of the investigational drug in subjects with relapsed/refractory hematolymphoid malignancies, so as to identify the optimal dose for subsequent formal clinical trials.
Trial Details
NCT Number NCT07338604
Lead Sponsor PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Collaborators: The First Affiliated Hospital of Soochow University
Conditions Hematolymphoid Malignancies
Enrollment 15 participants
Start Date 2025-12-12
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-14